Autism spectrum disorders (ASD) have common core symptoms which include increases in anxiety, and repetitive behaviors, with reduced sociability. It is widely believed that ASDs arise from subtle differences in the equilibrium between excitatory and inhibitory GABAergic neurotransmission. The electroneutral K+/Cl- co- transporter 2 (KCC2, or SLC12A5) is selectively expressed in the CNS after birth and allows neurons to maintain low intracellular Cl- concentrations an essential pre-requisite for the postnatal development of inhibitory neurotransmission. Consistent with its role in facilitating neuronal inhibition, deficits in KCC2 expression are evident in patients with ASDs and multiple autism animal models. KCC2 activity is subject to both positive and negative modulation via phosphorylation of serine's 940 and threonine residues 906 and 1007 respectively. Here, we will directly test if these regulatory processes influence the postnatal development of GABAergic inhibition, and the pathophysiology of ASDs. To do so we have created mice in which positive modulation of KCC2 activity by phosphorylation has been ablated via mutation of S940 to an alanine (S940A). T906/1007 are phosphorylated by with with-no-lysine kinases (WNKs), and we have also obtained line mouse lines with deficits in WNK activity. Preliminary studies using these new reagents have allowed us to formulate a novel hypothesis that will be tested here: The postnatal activation of KCC2 is facilitated by the reciprocal phosphorylation of S940 and dephosphorylation of T906/1007. Compromising these processes decreases the efficacy of GABAergic and directly contributes to the pathophysiology of ASDs. The experiments we will perform to test our hypothesis are detailed in the following aims.
Specific Aim 1. To test the hypothesis that phosphorylation of S940 in KCC2 is a critical determinant for the postnatal development of GABAergic inhibition.
Specific Aim 2. To test the hypothesis that WNK dependent phosphorylation of KCC2 slows the postnatal development of hyperpolarizing GABAergic inhibition.
Specific Aim 3. To test the hypothesis that slowing the postnatal development of GABAergic inhibition reproduces the core behavioral deficits of ASDs. Collectively, these experiments will provide key mechanistic insights into how deficits in KCC2 phospho-dependent modulation contribute to the pathophysiology of ASD. This information may lead to the development of more effective therapies targeting KCC2 activity to ultimately improve patient outcomes for ASDs. Such strategies may also be relevant for other neuropsychiatric disorders, such as epilepsy, neuropathic pain, and schizophrenia in which deficits of KCC2 activity are believed to be of significance.

Public Health Relevance

Autism spectrum disorders (ASD) affect 1 in 88 of children in the USA and have core symptoms of anxiety, increased repetitive behaviors and decreased sociability. Here we will examine the role that modifications in the postnatal development of synaptic inhibition due to alterations in the activity of KCC2 play in the pathophysiology of ASDs.This information may lead to the development of more effective therapies targeting KCC2 activity to ultimately improve patient outcomes for ASDs. .

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH106954-02
Application #
9149319
Study Section
Special Emphasis Panel (ZRG1-MDCN-P (57)S)
Program Officer
Panchision, David M
Project Start
2015-09-25
Project End
2017-08-31
Budget Start
2016-09-01
Budget End
2017-08-31
Support Year
2
Fiscal Year
2016
Total Cost
$206,250
Indirect Cost
$81,250
Name
Tufts University
Department
Neurosciences
Type
Schools of Medicine
DUNS #
039318308
City
Boston
State
MA
Country
United States
Zip Code
02111
Rifkin, Robert A; Moss, Stephen J; Slesinger, Paul A (2017) G Protein-Gated Potassium Channels: A Link to Drug Addiction. Trends Pharmacol Sci 38:378-392
Mukherjee, Jayanta; Cardarelli, Ross A; Cantaut-Belarif, Yasmine et al. (2017) Estradiol modulates the efficacy of synaptic inhibition by decreasing the dwell time of GABAA receptors at inhibitory synapses. Proc Natl Acad Sci U S A 114:11763-11768
Wobst, Heike J; Wesolowski, Steven S; Chadchankar, Jayashree et al. (2017) Cytoplasmic Relocalization of TAR DNA-Binding Protein 43 Is Not Sufficient to Reproduce Cellular Pathologies Associated with ALS In vitro. Front Mol Neurosci 10:46
Trattnig, Sarah M; Gasiorek, Agnes; Deeb, Tarek Z et al. (2016) Copper and protons directly activate the zinc-activated channel. Biochem Pharmacol 103:109-17
Nakamura, Yasuko; Morrow, Danielle H; Modgil, Amit et al. (2016) Proteomic Characterization of Inhibitory Synapses Using a Novel pHluorin-tagged ?-Aminobutyric Acid Receptor, Type A (GABAA), ?2 Subunit Knock-in Mouse. J Biol Chem 291:12394-407
Walker, Kendall R; Modgil, Amit; Albrecht, David et al. (2016) Genetic Deletion of the Clathrin Adaptor GGA3 Reduces Anxiety and Alters GABAergic Transmission. PLoS One 11:e0155799
Silayeva, Liliya; Deeb, Tarek Z; Hines, Rochelle M et al. (2015) KCC2 activity is critical in limiting the onset and severity of status epilepticus. Proc Natl Acad Sci U S A 112:3523-8
Nakamura, Yasuko; Darnieder, Laura M; Deeb, Tarek Z et al. (2015) Regulation of GABAARs by phosphorylation. Adv Pharmacol 72:97-146
Mircsof, Dennis; Langouët, Maéva; Rio, Marlène et al. (2015) Mutations in NONO lead to syndromic intellectual disability and inhibitory synaptic defects. Nat Neurosci 18:1731-6
Sivakumaran, Sudhir; Cardarelli, Ross A; Maguire, Jamie et al. (2015) Selective inhibition of KCC2 leads to hyperexcitability and epileptiform discharges in hippocampal slices and in vivo. J Neurosci 35:8291-6